Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (Nasdaq: LFWD) has received FDA 510(k) clearance for its ReWalk 7, the newest generation of its personal exoskeleton device designed for individuals with spinal cord injury (SCI). This seventh-generation wearable exoskeleton enables SCI patients to stand and walk again, featuring new enhancements and upgrades.
This milestone follows significant developments including the 2023 FDA clearance of ReWalk 6.0 for stairs and curbs usage, and the 2024 Centers for Medicare & Medicaid Services (CMS) national reimbursement policy approval for qualified beneficiaries. The company, which made history in 2014 with the first FDA-cleared exoskeleton medical device for SCI patients, will commence ReWalk 7 sales in the United States once the product becomes available.
Lifeward (NASDAQ: LFWD) reported strong financial results for Q4 and full year 2024, achieving record revenue of $7.5M for Q4 and $25.7M annually, representing an 85% year-over-year growth. ReWalk Personal Exoskeleton sales surged 130% in 2024, driven by Medicare coverage.
Q4 2024 highlights include: gross margin of 24.4% (45.4% non-GAAP), operating loss of $15.2M ($3.3M non-GAAP), and net loss of $15.3M ($1.73 per share). The company ended 2024 with $6.7M in cash and no debt, supplemented by a $5.0M registered direct offering in January 2025.
For 2025 guidance, Lifeward projects revenue of $28-30M, adjusted gross margins of 47-49%, and expects to reduce non-GAAP operating loss to approximately $1M by Q4 2025 through its Sustainable Growth Plan focusing on core product lines and streamlined operations.
Lifeward (Nasdaq: LFWD) and CorLife have finalized a partnership making CorLife the exclusive distributor of the ReWalk Personal Exoskeleton for Workers' Compensation claims. The partnership, announced on March 06, 2025, aims to expand access to ReWalk's technology for individuals with spinal cord injuries (SCI) sustained at work.
The ReWalk Personal Exoskeleton is a lower-body device enabling paralyzed individuals with SCI to stand and walk, being the only personal exoskeleton capable of handling stairs and curbs in real-world environments. CorLife, a division of Numotion, will leverage its network of credentialed providers and manage all workers' compensation claims submissions for the ReWalk system.
Lifeward (Nasdaq: LFWD) and MYOLYN have expanded their exclusive partnership to enhance patient access to the MyoCycle FES Cycling Therapy System for home use. The expanded agreement allows Lifeward to manage referrals and sales of MyoCycle Home products for patients transitioning from clinical to home use.
MyoCycle is a stationary exercise bike with integrated electrical stimulation designed for individuals with muscle weakness or paralysis due to conditions like spinal cord injury, multiple sclerosis, and stroke. Previously, Lifeward managed hospital and clinic-based sales of MyoCycle Pro nationwide, as well as home use sales for VA and Workers' Compensation beneficiaries.
Under the new arrangement, MYOLYN will continue directly servicing patients already discharged from therapy. Lifeward has established the necessary case management infrastructure to support anticipated growth in the MyoCycle product line, leveraging shared resources between MyoCycle and ReWalk Exoskeleton.
Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its Q4 and fiscal year-end 2024 financial results announcement for March 7, 2025, before market open.
CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast at 8:30 a.m. EST to discuss the results. The webcast will be accessible through the company's website at GoLifeward.com in the Investors section and will also be archived for future viewing.
Lifeward (NASDAQ: LFWD) announced CEO Larry Jasinski's retirement after 13 years of service, with his departure planned for Q2 2025. The board has formed a special committee to search for a successor, considering both internal and external candidates.
The company provided preliminary financial results for 2024, expecting revenue of $25.7 million, within their guidance of $25-26 million. Annual GAAP operating expenses are anticipated at $33.4 million, including $5.7 million in restructuring and impairment expenses. These figures are unaudited and subject to adjustment.
Due to the CEO transition, Lifeward has postponed its February 20th virtual investor event until later in 2025. The company will announce its 2025 financial outlook during its Q4 and full-year 2024 results call, scheduled for the week of March 10, 2025.
Lifeward (NASDAQ: LFWD) has finalized a reimbursement agreement with BARMER, Germany's second-largest statutory health insurer, for ReWalk Personal Exoskeletons. The agreement covers 8.5 million beneficiaries and formalizes the reimbursement process for medically eligible individuals.
BARMER has already provided 20 ReWalk Personal Exoskeletons to beneficiaries, leading Germany in exoskeleton coverage. This agreement means approximately 45% of people with Statutory Health Insurance in Germany now have coverage policies with defined reimbursement processes for personal exoskeletons.
This development follows recent expansion in reimbursement policies, including Medicare coverage in the U.S. and state coverage in Hungary. Lifeward is positioning itself for further expansion through submissions to Medicare Advantage Programs and other U.S. commercial payers.
Lifeward (Nasdaq: LFWD) has announced a virtual Investor Event scheduled for February 20, 2025, at 10:00 am EST. The event will feature presentations and Q&A sessions with executive leadership focusing on the company's strategy, key initiatives, and financial outlook.
The event will showcase innovative products from Lifeward's portfolio, including the ReWalk Exoskeleton for spinal cord injuries and the AlterG Anti-Gravity System for rehabilitation of orthopedic and neurological conditions. The virtual event will be accessible to investors, analysts, media, and other interested parties through a webcast, with both live access and replay available on the Investor Relations section of the Lifeward website at GoLifeward.com.
Lifeward (NASDAQ: LFWD) released a year-end letter highlighting key achievements in 2024 and outlining 2025 objectives. Major 2024 accomplishments include: establishing an Exoskeleton category with CMS for Medicare payment, delivering over 70 new ReWalk systems (double from previous year), building a pipeline of 100 qualified users, and successfully launching NEO and NEO+ additions to the AlterG product line.
The company raised $5 million in early January 2025 to support continued growth. Key 2025 priorities include maximizing exoskeleton execution, expanding AlterG penetration, and completing FDA and CE clearance for ReWalk 7 in H1 2025. The company aims to achieve non-GAAP operating profitability in H2 2026.
Lifeward (Nasdaq: LFWD) has cancelled its Extraordinary General Meeting of Shareholders that was scheduled for January 13, 2025. The company's Board of Directors has withdrawn the proposals outlined in their Definitive Proxy Statement, which was filed with the SEC on November 25, 2024. The Board plans to present these proposals at a future meeting later in 2025.